NASDAQ: IXHL
Incannex Healthcare Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their IXHL stock forecasts and price targets.

Forecast return on equity

Is IXHL forecast to generate an efficient return?

Company
-3,516.42%
Industry
30.55%
Market
76.96%
IXHL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IXHL forecast to generate an efficient return on assets?

Company
-305.54%
Industry
12.71%
IXHL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IXHL earnings per share forecast

What is IXHL's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.54
Avg 2 year Forecast
-$1.90

IXHL revenue forecast

What is IXHL's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$300.0k+206.12%
Avg 2 year Forecast
$500.0k+410.2%
IXHL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

IXHL revenue growth forecast

How is IXHL forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
206.12%
Industry
3.07%
Market
59.56%
IXHL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
IXHL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

IXHL vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
IXHL$0.59N/AN/A
FLGC$0.50$4.00+700.00%Strong Buy
TXMD$1.00N/AN/A
GELS$0.90N/AN/A
TLPH$0.49$6.00+1,124.49%Buy

Incannex Healthcare Stock Forecast FAQ

What is IXHL's earnings growth forecast for 2025-2026?

(NASDAQ: IXHL) Incannex Healthcare's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 80.88%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 71.14%.

Incannex Healthcare's earnings in 2025 is -$23,806,000.On average, 1 Wall Street analyst forecast IXHL's earnings for 2025 to be -$27,503,950, with the lowest IXHL earnings forecast at -$27,503,950, and the highest IXHL earnings forecast at -$27,503,950.

In 2026, IXHL is forecast to generate -$33,933,445 in earnings, with the lowest earnings forecast at -$33,933,445 and the highest earnings forecast at -$33,933,445.

If you're new to stock investing, here's how to buy Incannex Healthcare stock.

What is IXHL's revenue growth forecast for 2025-2026?

(NASDAQ: IXHL) Incannex Healthcare's forecast annual revenue growth rate of 206.12% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 3.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 59.56%.

Incannex Healthcare's revenue in 2025 is $98,000.On average, 1 Wall Street analysts forecast IXHL's revenue for 2025 to be $5,357,912, with the lowest IXHL revenue forecast at $5,357,912, and the highest IXHL revenue forecast at $5,357,912.

In 2026, IXHL is forecast to generate $8,929,854 in revenue, with the lowest revenue forecast at $8,929,854 and the highest revenue forecast at $8,929,854.

What is IXHL's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: IXHL) forecast ROA is -305.54%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 12.71%.

What is IXHL's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: IXHL) Incannex Healthcare's current Earnings Per Share (EPS) is -$1.39. On average, analysts forecast that IXHL's EPS will be -$1.54 for 2025, with the lowest EPS forecast at -$1.54, and the highest EPS forecast at -$1.54. In 2026, IXHL's EPS is forecast to hit -$1.90 (min: -$1.90, max: -$1.90).

What is IXHL's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: IXHL) forecast ROE is -3,516.42%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.